Your session is about to expire
← Back to Search
DOR/ISL for HIV/AIDS
Study Summary
This trial will investigate the safety and effectiveness of a drug in HIV-1 patients who have previously used it. No hypotheses are tested.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 35 Patients • NCT04233216Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My HIV-1 RNA level is 200 copies/mL or higher.I am currently in a clinical study for DOR/ISL by MSD.
- Group 1: DOR/ISL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are fresh recruits being sought for the trial?
"Affirmative. Clinicaltrials.gov provides evidence that this trial, which was posted on March 17th 2023, is actively recruiting participants right now. The research team aims to recruit 1300 individuals from two distinct sites."
What is the present enrollment for this investigation?
"Affirmative, the information posted to clinicaltrials.gov confirms that this trial is currently seeking applicants. The post was published on March 17th 2023 and has since been updated on March 21st of the same year. 1300 patients will need to be enrolled across 2 medical centres for successful completion of this study."
Is the DOR/ISL treatment protocol regarded as secure for patients?
"Given the pre-existing data which supports efficacy and multiple rounds of safety assessments, our team at Power assigned DOR/ISL a score of 3 on the 1 to 3 scale."
What are the projected effects of this clinical experiment?
"This 96 week research project aims to quantify the number of participants that suffer from adverse events. Secondary targets include measuring HIV-1 RNA levels at Week 96, and determining any evidence for drug resistance in participant's viral samples."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger